Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO
End Points,
Acelyrin said Monday that its lead drug izokibep failed to meet the primary endpoint in a Phase IIb/III trial in patients with…
Acelyrin said Monday that its lead drug izokibep failed to meet the primary endpoint in a Phase IIb/III trial in patients with…
MoonLake Immunotherapeutics says it’s cleared the bar in a Phase II trial of its IL-17A and IL-17F inhibitor in hidradenitis…
Produced in partnership with advocate, journalist and filmmaker Jasmine IVANNA Espy, "The Beacons: Illuminating HS Stories…
Produced in partnership with advocate, journalist and filmmaker Jasmine IVANNA Espy, "The Beacons: Illuminating HS Stories…